Latest Safety News

Page 12 of 252
Orezone Gold delivered record consolidated production of 59,674 ounces in the third quarter, with both Bomboré and Casa Berardi positioned for stronger output in the final quarter. The company has reiterated its 2026 production guidance despite a seven-day wildfire-related suspension at Casa Berardi.
Maxwell Dee
Maxwell Dee
15 Oct 2026
Aurelia Metals delivered a sharply stronger FY26, with revenue, EBITDA and net profit rising as Federation entered commercial production and gold output exceeded revised guidance. The next test is whether the company can convert that momentum into higher throughput while managing costs, safety and execution risk.
Maxwell Dee
Maxwell Dee
15 Oct 2026
Orora says strong Cans growth is no longer enough to offset weaker Saverglass earnings, with Group EBIT expected to decline in FY27. The company is targeting more than €30 million in Glass EBIT improvement by FY30 after a €449.7 million non-cash impairment.
Victor Sage
Victor Sage
14 Oct 2026
Orivium has begun construction of a modular processing plant in Orange, NSW, to test recovery of copper from Infinity Mining’s Cangai waste. The partner-funded facility could be operational within six months, but any revenue remains conditional on feedstock access, successful processing and metal sales.
Maxwell Dee
Maxwell Dee
14 Oct 2026
Prescient Therapeutics has reached the first planned review threshold in its PTX-100 Phase 2a lymphoma study, while a completed A$6.0 million raise extends funding beyond the December milestone. The review will assess safety and efficacy, but is not a study completion or a new clinical result.
Ada Torres
Ada Torres
13 Oct 2026
The US FDA has supported six of seven elements NeuroScientific Biopharmaceuticals put forward for its planned StemSmart Phase 2 Crohn’s disease trial. The remaining issue is a manufacturing control for viral contamination, while trial commencement remains targeted for the end of 2026 and subject to further requirements.
Ada Torres
Ada Torres
13 Oct 2026
Nyrada has received supportive written feedback from the US FDA on its proposed pathway for taking Xolatryp into a US Phase IIa heart-attack trial. The regulator identified no major issues, but additional information and stability data are still required before the planned IND submission in the first half of 2027.
Ada Torres
Ada Torres
13 Oct 2026
Pointerra3D delivered its strongest first-quarter customer receipts on record and returned to positive operating cash flow as enterprise deployments broadened across utilities, mining, transport and infrastructure. The ASX-listed software company ended September with A$1.95 million in cash, while several larger opportunities remain at proof-of-value or pending-award stages.
Victor Sage
Victor Sage
13 Oct 2026
Mesoblast has reported a sharp commercial step-up in FY2026, with Ryoncil generating US$115.2 million in net sales and total revenue reaching US$120.3 million. The company has also completed treatment in its 350-patient back-pain trial and refinanced its debt, but remains loss-making and expects to need more capital beyond the next 12 months.
Ada Torres
Ada Torres
12 Oct 2026
Crimson Consulting Australia has raised its unconditional cash offer for Kip McGrath to A$0.75 per share and secured unanimous board backing. The bid now carries no defeating conditions, but the final control outcome depends on acceptances before the 19 October deadline.
Victor Sage
Victor Sage
12 Oct 2026
Acrux says the FDA has confirmed the evidence package required to take its female testosterone spray into Phase III trials for postmenopausal women with HSDD. The agency also indicated the company may apply for three years of data exclusivity if the product reaches submission.
Ada Torres
Ada Torres
12 Oct 2026
Imricor has completed FDA review of the largest module in its US Premarket Approval application, with no deficiencies found in its ablation catheter or irrigation tubing. One operating-system issue remains for the RF-5000 System, but the company says it has already updated the software and is preparing its response.
Victor Sage
Victor Sage
8 Oct 2026

Browse the archive

Full archive